Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19

Chengyu Liu¹, Wanyao Yan², Jiajian Shi³, Shun Wang¹, Anlin Peng⁴, Yuchen Chen⁵* and Kun Huang³,⁵

¹ Department of Transfusion Medicine, Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; ² Department of Pharmacy, Wuhan Fourth Hospital, Wuhan, China; ³ Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; ⁴ Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China; ⁵ Tongji-Rongcheng Center for Biomedicine, Huazhong University of Science and Technology, Wuhan, China

The Coronavirus Disease 2019 (COVID-19) showed worse prognosis and higher mortality in individuals with obesity. Dyslipidemia is a major link between obesity and COVID-19 severity. Statins as the most common lipid regulating drugs have shown favorable effects in various pathophysiological states. Importantly, accumulating observational studies have suggested that statin use is associated with reduced risk of progressing to severe illness and in-hospital death in COVID-19 patients. Possible explanations underlie these protective impacts include their abilities of reducing cholesterol, suppressing viral entry and replication, anti-inflammation and immunomodulatory effects, as well as anti-thrombosis and anti-oxidative properties. Despite these benefits, statin therapies have side effects that should be considered, such as elevated creatinine kinase, liver enzyme and serum glucose levels, which are already elevated in severe COVID-19. Concerns are also raised whether statins interfere with the efficacy of COVID-19 vaccines. Randomized controlled trials are being conducted worldwide to confirm the values of statin use for COVID-19 treatment. Generally, the results suggest no necessity to discontinue statin use, and no evidence suggesting interference between statins and COVID-19 vaccines. However, concomitant administration of statins and COVID-19 antiviral drug Paxlovid may increase statin exposure and the risk of adverse effects, because most statins are metabolized mainly through CYP3A4 which is potently inhibited by ritonavir, a major component of Paxlovid. Therefore, more clinical/preclinical studies are still warranted to understand the benefits, harms and mechanisms of statin use in the context of COVID-19.

Keywords: SARS-CoV-2, COVID-19, statins, obesity, dyslipidemia, inflammation, immune response, thrombosis

INTRODUCTION

Obese individuals are more vulnerable to the SARS-CoV-2 caused Coronavirus Disease 2019 (COVID-19) (1−3). Obese people have ~46% higher risk for SARS-CoV-2 positive, ~74% increased odds for intensive care unit (ICU) admission and ~48% increased risk in deaths (4). Severe obesity [body mass index (BMI) ≥35] was significantly associated with the
need for invasive mechanical ventilation (IMV) (5), and was an independent predictor for intubation outcome (6). Moreover, with hyperlipidemia as a major link, obese individuals are prone to cardiovascular disease, hypertension, diabetes, myocardial infarction and stroke, which are among recognized risk factors for adverse COVID-19 outcomes (7–12) (Figure 1).

Prevalence of dyslipidemia was 18–39.7% as a comorbid condition in hospitalized COVID-19 patients (13–15). A population-based analysis on 61.4 million adult patients suggested that patients with hyperlipidemic state had 70% increased odds for catching COVID-19 (16). Moreover, COVID-19 patients may develop dyslipidemia that leads to life-threatening metabolic diseases and thrombotic complications (17–19), lipid-regulating agents are thus considered for possible therapeutic effects against COVID-19.

Statins are the most commonly used lipid-regulating drugs, 145.8 million people used statins in 2018 (20). Statins are HMG-CoA reductase inhibitors that can reduce serum total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels, and have other pleiotropic effects such as modulating immune response and alleviating inflammation (21–23). Structurally, statins are classified as lipophilic (atorvastatin, lovastatin, simvastatin, and fluvastatin) and hydrophilic (pravastatin and pitavastatin), while rosuvastatin has an intermediate behavior (24). Statin prescription is majorly under consideration for primary prevention of cardiovascular disease, and other pathologies such as thrombosis (25, 26). Rational use of different types of statins are recommended according to LDL-C lowering need, pre-existing cardiovascular events or related risk factors including dyslipidemia, diabetes, hypertension, and age (25, 26).

Observational studies have suggested protective effects of statins in COVID-19 patients. Statin use was associated with a 55% decreased risk for IMV (27), 22–30% reduced risk of ICU admission (28), and 30–47% lower risk for death (28–33) (Table 1). Moreover, statin use prior to admission was associated with 71% reduction in the odds of developing severe COVID-19 (34) and 73% for death (31). High-intensity statin use reduced the risk of death by 49% in COVID-19 patients with coronary artery disease patients (32) (Table 1). Possible explanations for these benefits of statins include their recognized cholesterol-reducing, anti-inflammatory and immunomodulatory capacities (21, 23, 49), and also their anti-viral, anti-thrombosis and anti-oxidative abilities (50–53) (Figure 1). However, possible side effects of statin should be considered, such as elevated creatine kinase (CK) and serum glucose levels, which are already elevated in severe COVID-19 (19, 54–56). Currently, clinical trials are being conducted worldwide to confirm the safety and benefits of statin use for COVID-19 patients, with criteria including mortality, thrombosis formation, need for ECMO or IMV, viral load etc. (Table 1).

Different SARS-CoV-2 variants cause surges of infections (57–60). Vaccines and antiviral therapies are powerful tools against COVID-19 (61, 62), yet data regarding the responses of obese individuals or statin users to these agents remain limited. It has been hypothesized that vaccines would offer reduced protection in obese individuals, based on evidence of immune cell dysregulation and alterations in inflammatory signaling pathways (4, 63). Given the immunomodulatory effects of statins, concerns have also been raised regarding possible interferences with COVID-19 vaccines. Moreover, cautions should be take that drug interactions between statins and some agents used in COVID-19 treatment, may lead to adverse effects (64–66).

Here, we provide a comprehensive update of the values, possible mechanisms, and noteworthy cautions regarding statin use in COVID-19. This review was conducted by consulting resources from peer-reviewed articles and/or official websites like WHO. Common search terms included “COVID-19 OR SARS-CoV-2” AND “statin OR lipid lowering”, etc.

VALUES AND MECHANISMS OF STATINS IN COVID-19

As effective drugs for reducing cholesterol, statins can prevent cardiovascular events which are key risk factors for COVID-19 infection and poor prognosis (9, 67–69). Cholesterol reduction allows statins to affect cell membrane structure and function, particularly lipid rafts that play important roles in viral entry and cellular processes like signal transduction (70–72). Moreover, by

---

**Table 1**

| SARS-CoV-2 positive | Hospitalization | Need for IMV |
|---------------------|----------------|-------------|
| ICU admission ↑     | Death ↑        | Need for IMV ↑ |
| Increase risks of adverse COVID-19 outcomes |
| Cardiovascular disease | Diabetes | Myocardial infarction |
| Hypertension | Stroke | ... |

**FIGURE 1** | Links between obesity, COVID-19 and statins. Obesity increased the risks of adverse COVID-19 outcomes, and dyslipidemia is a major link between obesity and COVID-19 severity. Statins may benefit COVID-19 patients, especially those with obesity and dyslipidemia, due to their multiple effects.
TABLE 1 | Associations between statins and COVID-19 outcomes, and clinical trials regarding statin use in COVID-19.

| References                | Type of study       | Study cohort                                                                 | Key findings                                                                                                                                   |
|---------------------------|---------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Song et al. (27)          | Retrospective study | 249 adult patients hospitalized with COVID-19 in Rhode Island, USA             | After adjusting for age, sex, race, cardiovascular disease, chronic pulmonary disease, diabetes, and obesity, statin use was significantly associated with decreased risk for IMV [aOR = 0.45, 95% CI: 0.20–0.99]. |
| Vahedian-Azimi et al. (29)| Meta-analysis       | 32,715 patients in 24 studies                                                | Statin use was associated with significant reductions in ICU admission (OR = 0.78, 95% CI: 0.58–1.06; n = 10; P = 58.5%) and death (OR = 0.70, 95% CI: 0.55–0.88; n = 21; P = 82.5%) outcomes, with no significant effect on tracheal intubation (OR = 0.79; 95% CI: 0.57–1.11; n = 7; P = 89.0%). |
| Zhang et al. (29)         | Retrospective study | 13,981 cases of confirmed COVID-19 admitted in 21 hospitals from Hubei Province, China | The risk for 28-day all-cause mortality was 5.2 and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted HR of 0.58; the use of statins in hospitalized subjects with COVID-19 was associated with a lower risk of all-cause mortality and a favorable recovery profile. |
| Lee et al. (30)           | Nested case-control study | 10,448 COVID-19 patients who were hospitalized in Korea | Statins were prescribed in 533 (5.1%) patients. After adjusting for age, sex, and comorbidities, Cox regression showed a significant decrease in hazard ratio associated with the use of statins [aHR = 0.637 (95% CI, 0.425–0.953); P = 0.0283]. Statin use is correlated with lower mortality in COVID-19 patients. |
| Memel et al. (31)         | Cohort study        | 1,179 patients, 676 (57%) were male, 443 (37%) were >65 years old, and 493 (46%) had a BMI ≤30 | Inpatient statin use reduced the hazard of death (HR, 0.566; P = 0.008). This association held among patients who did and those did not use statins before hospitalization [HR, 0.270 (P = 0.003) and 0.493 (P = 0.04), respectively]. Statin use was associated with improved time to death for patients aged >65 years but not for those <65 years old. Statin use during hospitalization for SARS-CoV-2 infection was associated with reduced 28-day mortality rates. |
| Choi et al. (32)          | Retrospective study | 5,375 COVID-19 patients admitted to Mount Sinai Health System hospitals in New York | Compared to non-statin users, both low-to-moderate-intensity (aHR = 0.62, 95% CI 0.51–0.76) and high-intensity statin users (aHR = 0.53, 95% CI 0.43–0.65) had a reduced risk of death. Subgroup analysis of 723 coronary artery disease patients showed decreased mortality among high-intensity statin users compared to non-users (aHR = 0.51, 95% CI 0.36–0.71). Statin use in patients hospitalized with COVID-19 was associated with a reduced in-hospital mortality. The protective effect of statin was greater in those with coronary artery disease. |
| Rodriguez-Nava et al. (33)| Retrospective cohort study | 87 adult patients with COVID-19 admitted to community hospital ICU in Evanston, IL, USA | In the multivariable Cox proportional hazards regression model, atorvastatin non-users had a 73% chance of faster progression to death compared with atorvastatin users (when probability = HR/HR + 1). |
| Daniels et al. (34)       | Retrospective single-center study | 170 hospitalized patients with COVID-19 and 5,281 COVID-negative subjects at University of California San Diego Health | Statin use prior to admission was associated with reduced risk of severe COVID-19 (aOR = 0.29, 95% CI 0.11–0.71, P < 0.01) and faster time to recovery among those without severe disease (aHR for recovery 2.69, 95% CI 1.36–5.33, P < 0.01). The association between statin use and severe disease was smaller in the COVID-negative cohort (P for interaction = 0.07). |
| Rossi et al. (35)         | Follow-up study     | 71 consecutive patients with a pre-existing chronic cardiovascular disease, who become ill from COVID-19 | Among 42 statin users, 16/42 (38.1%) took a hydrophilic statin (rosuvastatin in 14 patients and pravastatin in 2), while 26/42 (61.9%) a lipophilic statin (atorvastatin in 22 patients, and simvastatin in 4). The group of lipophilic statins demonstrated a significant reduction in mortality respect both patients who do not take statins, and patients who assumed hydrophilic statins. |
| Saeed et al. (36)         | Observational study | 4,252 patients (65 ± 16 years old; 47% female) were admitted with COVID-19, 37% (n = 1,570) were Hispanic | Patients with diabetes mellitus on a statin (n = 983) reduced cumulative in-hospital mortality (24 vs. 39%; P < 0.01) than those not on a statin (n = 1,283). Statin use in people with diabetes was associated with a reduced risk of in-hospital mortality during COVID-19. No difference in hospital mortality was noted in patients without diabetes mellitus on or off statin (20 vs. 21%; P = 0.82). |

(Continued)
| References | Type of study | Study cohort | Key findings |
|------------|--------------|--------------|--------------|
| De Spiegeleer et al. (37) | Retrospective study | 154 COVID-19 diagnosed residents aged 86 ± 7 years in 2 Belgian nursing homes | Statin intake is associated with the absence of symptoms during COVID-19 (OR 2.91; 95% CI 1.27–6.71), which remained statistically significant after adjusting for covariates (aOR 2.65; 95% CI 1.13–6.68). In conclusion, statin intake in older, frail adults could be associated with a considerable beneficial effect on COVID-19 clinical symptoms. |
| Lala et al. (38) | Retrospective study | 2,736 patients with COVID-19 admitted to 1 of 5 Mount Sinai Health System hospitals in New York City | Among 1,296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of in-hospital mortality within 30 days in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, $P < 0.001$). |
| Gupta et al. (39) | Retrospective study | 2,626 patients admitted with COVID-19, of whom 961 (36.2%) were antecedent statin users. Among 1,296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of in-hospital mortality within 30 days in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, $P < 0.001$). |
| Byttebier et al. (40) | Retrospective observational case-control study | 959 COVID-19 patients admitted consecutively to four Belgian hospitals | Treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR = 0.33; 95% CI 0.17–0.69). In-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives. |
| Ayeh et al. (41) | Retrospective study | 4,447 patients hospitalized at the Johns Hopkins Hospital and affiliated hospitals with COVID-19, 594 (13.4%) were exposed to statins on admission. | The average treatment effect of statin use on COVID-19-related mortality was RR = 1.00 (95% CI: 0.99–1.01, $P = 0.928$), while its effect on severe COVID-19 infection was RR = 1.18 (95% CI: 1.11–1.27, $P < 0.001$). |
| Kollias et al. (42) | Meta-analysis | 41,807 patients, 14% with statin use | Statin use was not associated with altered mortality, but with an 18% increased risk of severe COVID-19 infection. |
| Lee et al. (43) | Two independent nationwide cohort studies | 214,207 patients older than 20 years who underwent tests for SARS-CoV-2 infection in South Korea | Prior statin use is related to a decreased risk of worsening clinical outcomes of COVID-19 and length of hospital stay but not to that of SARS-CoV-2 infection. |
| Kow et al. (44) | Meta-analysis | 8,990 COVID-19 patients in 4 studies | The pooled analysis revealed a significantly reduced hazard for fatal or severe disease with the use of statins (Pooled HR = 0.70; 95% CI 0.53–0.94) compared to non-use of statins in COVID-19 patients. |
| Tan et al. (45) | Retrospective study | 717 patients admitted to a tertiary center in Singapore for COVID-19 infection. | Statin use was independently associated with lower ICU admission. |

**Study Title** | **Status** | **Locations** | **Summary** | **Key results** |
|-------------|-----------|--------------|-------------|---------------|
| COVID-19 related clinical trials of statins | Completed | Mash D. Hospital, Tehran, Iran, Islamic Republic of Iran | This study investigates the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients (Actual Enrollment: 600 participants) with COVID-19 using a 2 × 2 factorial design. | In adults with COVID-19 admitted to the ICU, atorvastatin was not associated with a significant reduction in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality compared with placebo. The treatment was safe (46). |
TABLE 1 | Continued

| Study Title | Status | Locations | Summary | Key results |
|-------------|--------|-----------|---------|-------------|
| Effectiveness and safety of medical treatment for SARS-CoV-2 (COVID-19) in Colombia (NCT04359095) | Completed | 6 hospitals in Colombia including Clínica santa María del lago, Clínica Reina Sofia, Fundación Cardio Infantil, etc. | The study assesses the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients. Six hundred and forty-nine patients agreed to participate and were enrolled in this study; among them, 633 (97.5%) were included in the analysis. The primary endpoint was 28-day all-cause mortality. | The combined use of emtricitabine with tenofovir disoproxil plus colchicine and rosuvastatin reduces the risk of 28-day mortality and the need for IMV in hospitalized patients with COVID-19 (47). |
| The impact of statin therapy in the COVID-19 patients (NCT06238402) | Completed | Deniz Demirci Antalya, Turkey | The study is retrospective single-center review of COVID-19 patients (actual Enrollment: 707 participants). The study population was divided into patients who received a statin vs. those who did not receive a statin before the hospitalization. The primary outcome was in-hospital mortality during the follow-up period. | No results posted |
| Statin therapy and COVID-19 infection (NCT04407273) | Completed | Facultat de Medicina i Ciències de la Salut de Reus, Reus, Tarragona, Spain | This is a retrospective observational multicenter study. The SARS-CoV-2 severity of 2,159 COVID-19-infected patients with statin therapy was classified into 9 grades. Primary outcome is the WHO SARS-CoV-2 scale of severity (9 grades) achieved by COVID-19 patients, admitted in the hospital, with and without background statin therapy comparable in age and gender distribution. | No results posted |
| Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (NCT02735707) | Recruiting | 322 hospitals worldwide | The purpose of this study is to evaluate the effect of about 50 interventions, including statin use, to improve outcome of patients admitted to ICU with community-acquired pneumonia including COVID-19. | No results posted |
| Colchicine/statins for the prevention of COVID-19 complications (COLSTAT) trial (NCT04472611) | Recruiting | 4 hospitals in United States including Bridgeport Hospital, Greenwich Hospital, Yale New Haven Hospital System, Lawrence and Memorial Hospital | This is a randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2 (Estimated Enrollment: 486 participants). The primary endpoint is the 30-day composite of progression to severe COVID-19 disease. | No results posted |
| Managing endothelial dysfunction in critically ill COVID-19 patients at LAUMCRH (NCT04813471) | Recruiting | LAUMCRH Beirut, Lebanon | The study seeks to target endothelial dysfunction in critically ill patients with COVID-19 by giving them an endothelial protocol (L-arginine, Folic Acid, Statin, Nicorandil, Vitamin B complex) and monitor clinical outcome in those patients. | No results posted |
| Atorvastatin as adjunctive therapy in COVID-19 (NCT04380402) | Recruiting | Mount Auburn Hospital Cambridge, Massachusetts, United States | This study assesses whether adjunctive therapy of COVID-19 with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome. | No results posted |

(Continued)
### Study Title
- Helping alleviate the longer-term consequences of COVID-19 (HEAL-COVID) (NCT04801940)
- Combination therapies to reduce carriage of SARS-CoV-2 and improve outcome of COVID-19 in ivory coast: a phase randomized IIb trial (NCT044666241)
- Statin treatment for COVID-19 to optimize neurological recovery (NCT04904536)
- A study of anticoagulation treatment patterns and outcomes of participants hospitalized with coronavirus disease 2019 (COVID-19) in Japan (NCT04828772)
- Managing endothelial dysfunction in COVID-19: a randomized controlled trial at LAUMC (NCT04631536)
- Atorvastatin for reduction of 28-day mortality in COVID-19: RCT (NCT04952350)
- Study of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19 (NCT04348695)
- Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomized controlled trial (NCT04333407)
- Coronavirus response—active support for hospitalized COVID-19 patients (NCT04343001)
- A study of anticoagulation treatment patterns and outcomes of participants hospitalized with coronavirus disease 2019 (COVID-19) in Japan (NCT04828772)
- Statin treatment for COVID-19 to optimize neurological recovery (NCT04904536)
- Managing endothelial dysfunction in COVID-19: a randomized controlled trial at LAUMC (NCT04631536)
- Atorvastatin for reduction of 28-day mortality in COVID-19: RCT (NCT04952350)
- Study of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19 (NCT04348695)
- Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomized controlled trial (NCT04333407)
- Coronavirus response—active support for hospitalized COVID-19 patients (NCT04343001)

### Key results
- No results posted
- No results posted
- No results posted
- Compared with no treatment, anticoagulants may reduce all-cause mortality but the evidence comes from non-randomized studies and is very uncertain (48).
- No results posted
- No results posted
- No results posted
- No results posted

### Data was acquired as of April 16, 2022. aHR, adjusted hazard ratio (HR); aOR, adjusted odds ratio (OR); BMI, body mass index; CI, confidence interval; ICU, intensive care unit; IMV, invasive mechanical ventilation; I^2, I-squared statistics indicating between-study heterogeneity; RR, risk ratio.
reducing intermediate products of cholesterol biosynthesis, statins downregulate protein isoprenylation to regulate numerous signaling pathways including immune responses (73). Hyperactivation of immune responses, elevated systematic inflammation, increased oxidative stress, and thrombosis events have been observed in severe COVID-19, especially among those with obesity or cardiovascular diseases, while statins have shown suppressive effects against these processes (Figure 1).

**Antiviral Effects**

SARS-CoV-2 infection initiates from cell entry by attaching to its receptor ACE2 (70, 71). The cholesterol-rich membrane lipid rafts is crucial for this process. By reducing cholesterol, disrupting lipid raft composition, altering membrane receptor assembly and localization, statins interfere with virus fusion and entry in HIV models (51, 74). Potential mechanism is that statins-mediated blockade of HMG-CoA reductase leads to inhibition of Rho guanosine triphosphatase, a key contributor to clustering of lipid raft-associated receptors (74, 75). Statins may increase ACE2 levels under disease situations with unknown clinical relevance (76), and simvastatin significantly affected SARS-CoV-2 cell entry through displacing ACE2 on lipid rafts (77) (Figure 2). Simvastatin can also reduce SARS-CoV-2 replication (77). Viral infection increases HMG-CoA reductase activity and cholesterol synthesis to assist viral replication, which explains the negative impact of statins on viral replication (78, 79) (Figure 2). Viral assembly and release following replication can be suppressed by statins through inhibiting mevalonate synthesis and intracellular cholesterol levels (80, 81). Whether statins similarly affect the assembly and release of SARS-CoV-2 remain unknown.

Although multiple statins have showed antiviral effects against different viruses, a study suggested higher efficacy for lipophilic statins against Zika viral replication, possibly because they can enter cells via passive transport to reach higher intracellular concentrations (82). Moreover, comparison between the survival curves of patients with a pre-existing chronic cardiovascular disease indicated a significant reduction in mortality in lipophilic statin users vs. hydrophilic group and non-users group (35). Therefore, it will be critical to understand whether and how the type, dose and duration of statin therapy affect antiviral effects and subsequently the outcome of SARS-CoV-2 infection.

**Anti-inflammatory and Immunomodulatory Effects**

Exacerbated inflammation is a pathological hallmark of COVID-19 (83). During severe COVID-19, a generalized inflammatory state is caused by cytokine storm due to hyperactivation of host immune system, leading to lesions in multiple organs and even death (84). Upon SARS-CoV-2 invasion, antigen-presenting cells recognize the pathogen via Toll-like receptors (TLRs) and activates two main downstream pathways, MyD88- and TRIF-dependent pathways, both leading to NF-κB activation (85–88). NF-κB initiates the first stage of inflammasome activation and induces the production of pro-inflammatory factors, including interleukin-6 (IL-6), a key cytokine associated with COVID-19 severity and mortality (89–91). Activation of NLRP3 inflammasome involves in response to infection of
RNA viruses including SARS-CoV-2 (92–95). Patients with a reduced immune fitness and pre-existing systemic inflammatory state, such as obesity or cardiovascular diseases, are prone to demonstrate dysregulated NLRP3 inflammasome activity and pro-inflammatory cytokines expression, resulting in severe COVID-19 (92, 96, 97).

Statins are known for anti-inflammatory and immunomodulatory effects (Figure 2). Statins can decrease TLRs expression, suppress MYD88-NF-κB pathway and the levels of pro-inflammatory cytokines like IL-6, IL-8, TNF-α and MCP-1, thereby altering inflammatory pathway to reduce cell damage (21, 98–100). Statins directly regulate NLRP3 inflammasome (101), or suppress TLR4-MyD88-NF-κB pathway to inhibit its activation (102), thus downregulate cytokines including IL-18 and IL-1β (103, 104). Immunomodulatory actions also underlie statins’ beneficial effects in pathologic status. For example, statins block mevalonate generation required for T cell proliferation (105), repress MHC-II molecules that are critical for presenting antigen to T cells (23, 106), and suppress maturation of dendritic cells (107), therefore may alleviate hyperactivation of immune response. Rosuvastatin promotes the differentiation of peripheral blood monocytes into anti-inflammatory M2 macrophages (49, 108); atorvastatin suppresses proliferation of naïve Th0 cells and secretion of Th1 pro-inflammatory cytokines, while enhances secretion of Th2 anti-inflammatory cytokines (109).

Clinical studies indicate that statins decrease serum CRP levels (110), an inflammatory biomarker and risk factor for adverse COVID-19 outcomes (111). Importantly, in-hospital statin use is significantly associated with ameliorated inflammatory responses, as reflected by lower levels of circulating CRP, IL-6 and neutrophil counts in statin users (29). Correspondingly, simvastatin downregulated SARS-CoV-2-infection-triggered inflammation in human neutrophils, peripheral blood monocytes, and lung epithelial Calu-3 cells, showing its anti-inflammatory effect both at the site of viral infection and systemically (77). Statin-mediated CRP reduction can be achieved by lowering LDL-C, suppressing Rac-1 activation and increasing apolipoprotein A-I, all of which alleviate inflammation and subsequent CRP generation (112). Notably, for PCSK9 inhibitors, another class of lipid-lowering drugs that significantly decreases LDL-C but not inflammatory markers like CRP (113, 114), evidence is lacked so far regarding their possible benefits on COVID-19 outcomes, while deeper investigation is needed. Since COVID-19 patients with obesity are prone to immune cell dysregulation and elevated inflammations, further studies are warranted to explore whether and how statins may protect them from COVID-19.

**Anti-thrombosis Effects**

Thrombosis are among the most frequent complications in COVID-19 patients, especially in critically ill cases (115–117), and elevated D-dimer levels show prognostic significance for poor outcomes (7, 116, 118). Therefore, prevention/allolevation of thrombosis is a key to COVID-19 treatment, especially for obese patients who are prone to ICU admission and thromboembolic events.

Statins can reduce the occurrence of deep vein thrombosis and pulmonary embolism (52, 119–122), common thrombotic events in COVID-19 cases (123, 124). The anti-thrombosis impact of statins not only relates to its cholesterol-lowering effects and to plaque stabilization (125), but also involves lipid-lowering independent inhibitory effect on platelets activation and coagulation cascade, major pathways for thrombosis formation (18, 52, 126). Statins exert antiplatelet effect via downregulating prothrombotic factors including platelet thromboxane A2, NOX2 (the catalytic subunit of NADPH oxidase), oxidized low-density lipoprotein (oxLDL) and its receptor CD36 (127–129), and via promoting endothelial nitric oxide synthase (eNOS) which improves production of platelet nitric oxide (NO), a potent inhibitor of platelet activation and aggregation (130, 131).

Statins also interfere with clotting system and coagulation cascade. Statins downregulate the expression and activity of tissue factor which initiates the extrinsic pathway of coagulation (132–136), and reduce the serum level of plasminogen activator inhibitor (137); meanwhile, statins upregulate KLF2 that has anticoagulant and atheroprotective effects (138, 139), promote thrombomodulin expression and fibrinolytic activity (140–143). Since a mutual relationship exists between immune activation and thrombus formation (144), the anti-inflammatory actions of statins may also contribute to thrombosis suppression (18).

The anti-thrombosis effect of statins has been widely investigated in patients at risk for cardiovascular disease or those with established atherosclerosis, and varies from different statins (145, 146), but their impacts on COVID-19-related thrombosis remain largely unknown. A clinical trial in ICU admitted COVID-19 patients observed lower rate of thrombosis event in atorvastatin group, although without significant association, suggesting possible anti-thrombosis role of atorvastatin in COVID-19 cases; assessment of outcomes after long-time follow-up is ongoing (46).

**Anti-oxidative Effects**

Excessive reactive oxygen species (ROS) is associated with high neutrophil to lymphocyte ratio in critically ill COVID-19 (147). In monocytes and macrophages, SARS-CoV-2 infection triggers mitochondrial ROS production, induces HIF1α stabilization and consequently promotes glycolysis which facilitates viral replication (148). Overwhelming oxidative stress also causes local or systemic damages, induces thrombosis, contributing to COVID-19 severity (149).

Statins exerts anti-oxidative effect by attenuating NF-κB activation, reducing circulating oxLDL and their uptake by macrophages, inhibiting oxidant enzymes such as NADPH oxidase and myeloperoxidase, and upregulating the activity of antioxidant enzymes like catalase and paraoxonase (53, 150). Additionally, statins downregulate NOX2-derived oxidative stress, ultimately exerting antiplatelet effects (128, 151–153). Despite these anti-oxidative effects which possibly benefits COVID-19 treatment, statins may induce ROS production, mediate redox imbalance and consequent cellular oxidative damage, especially under excessive or long-term statin use (154).
CLINICAL TRIALS REGARDING STATIN USE AND COVID-19

Currently, among clinical trials regarding statin use and COVID-19, two have published results, while the others remain uncompleted or have not posted results (Table 1). In INSPIRATION/INSPIRATION-S study (NCT04486508) conducted in Iran ICU admitted COVID-19 patients, atorvastatin (20 mg/day) was not associated with a significant reduction in the composite of thrombosis, ECMO treatment, or all-cause mortality; however, atorvastatin treatment was safe, and may have clinical importance with lower overall event rates (46). Another study (NCT04359095) was conducted in Colombia (47), emtricitabine with tenofovir disoproxil (200/300 mg/day for 10 days) plus colchicine and rosuvastatin (0.5 mg and 40 mg/day for 14 days) combination reduced the risk of 28-day all-cause mortality by 22%, and lowered the need for IMV (47). These findings indicated safety and potential benefits of statins for COVID-19 treatment, yet the therapeutic effect varies from cohort and medications. More randomized controlled trials are therefore warranted to assess the effect of statin administration alone or in combination with regards of medication dose and duration, and to evaluate the influence of chronic statin use on COVID-19-related in-hospital events or long-term complications.

CAUTIONS ABOUT STATINS USE IN COVID-19

Although statins are generally well-tolerated, for COVID-19 patients especially those with obese or chronic statin use, cautions are required for potential risks of statins-associated muscle symptoms, liver injury, new-onset diabetes, renal injury, and neurological and neurocognitive disorders, which may also result from severe COVID-19 (68, 84, 126, 155, 156) (Figure 3).

Statin-associated muscular symptoms (SAMS) are principal cause of poor patient compliance that contribute to adverse outcomes (157, 158). SAMS include fatigue, weakness and pain, possibly accompanied by elevated serum CK levels and activity (54), while similar symptoms also present at early onset of COVID-19 (159). Therefore, for COVID-19 patients who use statins, careful monitoring muscle symptoms and CK levels are necessary; when muscle symptoms occur, assessment and approaches for statin intolerance may be considered (68, 160).

Statins-associated hepatotoxicity may add to COVID-19 related liver injury that potentially caused by psychological stress, systemic inflammation, etc., especially among obese individuals at higher risk of liver dysfunction (161–163). It has been suggested to avoid statin use in the case of severe liver damages, liver failure, and decompensated cirrhosis (24).

COVID-19 may induce or accelerate type 2 diabetes mellitus (T2DM) development as one of its acute and suspected long-term complications (19, 56), while statin may increase incidence of new-onset T2DM, which appears to be more common in obese patients (55, 164, 165). Despite the risk of T2DM, the cardiovascular benefits of statins should not be masked (166).

Therefore, statin therapy can be continued in such patients with glucose monitoring, to achieve better glycemic control and avoid developing metabolic disorders after SARS-CoV-2 infection.

Clinicians should also be cautious when treating statin users with COVID-19 who show renal or neurological symptoms and relevant laboratory abnormalities. Renal dysfunction can be caused by SARS-CoV-2 infection and is associated with COVID-19 poor prognosis (167–169); whether statin-associated renal toxicity (170, 171) exacerbates COVID-19-related renal dysfunction remains unclear. There are also concerns regarding whether use of statin (especially lipophilic ones that can cross the blood-brain barrier) may worsen clinical manifestations of nervous system in COVID-19 patients, given their side effects of causing neurological disorders (171, 172).

Caution is also necessary for drug interaction during COVID-19 management. Most statins are predominantly metabolized by CYP450 enzymes, mainly through CYP3A4 (64). Therefore, concomitant administration of CYP3A4 inhibitors, such as some macrolides (clarithromycin/telithromycin/erythromycin) and antiretroviral drugs (lopinavir/ritonavir), with statins can increase the risk of adverse events (68, 173). For severe COVID-19 patients treated with IL-6 receptor blocker tocilizumab, rosuvastatin is recommended (68). Additionally, decreased LDL-C was observed in some severe COVID-19 cases (174, 175). Such finding may due to a more intensive lipid-lowering treatment in patients with high cardiovascular risk who are more vulnerable to COVID-19 (176), and deeper analysis is warranted to better prescribe appropriate intensity statin therapy.

STATINS AND COVID-19 VACCINES

The impact of statins on vaccine efficacy remain controversy. Take influenza vaccine for example, a clinical trial suggested immunosuppressive effect of chronic statin medication may weaken the immune response to vaccine (177), whereas another study indicated that statin did not modify influenza vaccine effectiveness (178). Presently, multiple COVID-19 vaccines have been approved, notably, vaccination participants with BMI ≥ 30 had a smaller infection risk reduction than those with BMI < 30 (179), and central obesity (higher waist circumference) is associated with lower neutralizing antibody titers following vaccination (180). Presently, no evidence suggests statin may affect COVID-19 vaccine effectiveness.

STATINS AND COVID-19 ANTIVIRALS

SARS-CoV-2 variants may have substantial immune evasiveness that weakens vaccine protection due to spike protein mutations (57–60). Small molecular antivirals have reduced hospitalization rate and mortality in patients with promising safety (181, 182), among which Paxlovid stands out by reducing the risk of COVID-19-related hospital admission or death by 89% (183, 184). Paxlovid consists of a SARS-CoV-2 main protease inhibitor PF-07321332, and an anti-HIV drug ritonavir that boosts the effectiveness of protease inhibitors (184). However, co-administration of statins and Paxlovid may increase statin
exposure and the risk of adverse effects including muscle symptoms and liver toxicity, because ritonavir potently inhibits CYP3A4 through which lipophilic statins are predominantly metabolized (64–66). Therefore, when such concomitant use is needed, it is possible to continue rosuvastatin therapy starting a low dose and titrating up (68, 156). More studies are needed to clarify the possible risks regarding co-administration of statins and antivirals, to find a proper regimen, and to explore whether obesity and dyslipidemia may interfere the efficacy of antivirals.

CONCLUSION AND FUTURE PERSPECTIVES

Current data suggest that statins are safe for COVID-19 patients and may exert therapeutical benefits. Generally, there is no necessity to discontinue statin use, and no evidence suggesting interference between statins and COVID-19 vaccines. However, cautions should be taken to achieve proper medication for statin users with COVID-19, considering possible side effects and drug interaction (Figure 3). Two major cautions are: Proper type of statin. Compared to hydrophilic statins, lipophilic statins enter cells via passive transport to reach higher intracellular concentrations, and have a larger distribution volume, thus may be more protective in respect of anti-viral ability. Intensity of statin therapy. Hypolipidemia is harmful. Decreased LDL-C is observed in some COVID-19 patients and associated with COVID-19 severity (174, 175), yet such findings may due to a more intensive lipid-lowering treatment in patients with high cardiovascular risk who are more vulnerable to COVID-19 (176). Low-, moderate-, high-intensity statin therapy should be applied according to specific LDL-C lowering needs. Importantly, careful monitoring of LDL-C, CK, blood glucose and liver function is recommended in context of COVID-19.

Currently known impacts of statins in COVID-19 are mostly based on observational studies and may vary due to heterogeneity in different trials/cohorts. To address the effect of statins in COVID-19 patients, especially in those with obesity or dyslipidemia-related diseases, randomized controlled trials with proper patient stratification are warranted. Moreover, experimental evidence of how different statins act in COVID-19 models are rare, highlighting the importance of related studies.

AUTHOR CONTRIBUTIONS

CL, WY, YC, and KH: conceptualization. CL, WY, YC, and JS: writing—original draft preparation. CL, YC, SW, AP, and KH: writing—review and editing. All authors have read and agreed to the final version of the manuscript.

FUNDING

This work was supported by the Natural Science Foundation of China (31971066), the China Postdoctoral Science Foundation (2021M700050), the Natural Science Foundation of Hubei Province (2021CFA004 and 2021CFB250), and the Postdoctoral Innovation Research Program of Hubei Province.

ACKNOWLEDGMENTS

We sincerely appreciate the investigators and authors who have contributed to this field and apologize that we could not discuss and cite all of them in this review due to space limitations.
REFERENCES

1. Cai QX, Chen FJ, Wang T, Luo F, Liu XH, Wu QK, et al. Obesity and Covid-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. (2020) 33:1192–8. doi: 10.2337/dc20-00576
2. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20133 UK patients in hospital with Covid-19 using the isaric who clinical characterisation protocol: prospective observational cohort study. BMJ. (2020) 369:m1985. doi: 10.1136/bmj.m1985
3. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. (2020) 71:896–7. doi: 10.1093/cia/ciaa415
4. Popkin BM, Du SF, Green WD, Beck MA, Alaghith T, Herbst CH, et al. Individuals with obesity and Covid-19: a global perspective on the epidemiology and biological relationships. Obes Rev. (2020) 21:e13128. doi: 10.1111/obr.13128
5. Simonnet A, Chetboun M, Poissy J, Raverdy V, Nourjou L, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. (2020) 28:1195–9. doi: 10.1002/oby.22831
6. Palaiodimos L, Kokkinidis DG, Li WJ, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a Cohort of patients with Covid-19 in the Bronx, New York. Metabolism. (2020) 108:154262. doi: 10.1016/j.metabol.2020.154262
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
8. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019. Pneumonia in Wuhan, China. JAMA Intern Med. (2020) 180:934–43. doi: 10.1001/jamainternmed.2020.0994
9. Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins regulates muscle-liver-fat axis by musclin under overnutrition in female mice. Peptides on diabetic complications. Curr Protein Pept Sci. (2020) 21:e13128. doi: 10.1111/obr.13128
10. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 15919. Patients infected with coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. JAMA Intern Med. (2020) 180:934–43. doi: 10.1001/jamainternmed.2020.0994
11. Zhang W, Yang D, Yuan Y, Liu C, Chen H, Zhang Y, et al. Muscular G9a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins), may be type 2 diabetes mellitus: the central role of cell dysfunction, apoptosis and exploration of possible mechanisms. Cells. (2020) 9:2475. doi: 10.3390/cells9112475
12. Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. (2021) 328:44–51. doi: 10.1016/j.atherosclerosis.2021.05.016
13. Lefer DJ, Statins as potent antiinflammatory drugs. Circulation. (2002) 106:2041–2. doi: 10.1161/01.circ.106.2041.012731
14. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. (2002) 42:835–45. doi: 10.1177/0022321020421004
15. Gomez-Mesa JE, Galindo-Coral S, Montes MC, Munoz Martin AJ. The effects of arbs, aceis, and statins on clinical outcomes of covid-19 related outcomes-brief report: a national population-based cohort study. Arterioscler Thromb Vasc Biol. (2021) 41:e175–82. doi: 10.1161/ATVBAHA.120.315551
16. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice. Med Clin North Am. (2017) 101:689–99. doi: 10.1016/j.mcna.2017.03.001
17.יבהד-Azimi A, Mohammad SM, Heidari Beni F, Banach M, Gudina M, et al. Improved covid-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci. (2021) 17:579–95. doi: 10.5114/ams.132950
18. Zhou FJ, Yu TQ, Chen FJ, Wang TQ, Luo FX, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with covid-19. Cell Metab. (2020) 32:176–87.e4. doi: 10.1016/j.cmet.2020.06.015
19. Lee HY, Aih J, Park I, Kyung Kang C, Won SH, Wook Kim D, et al. Beneficial effect of statins in covid-19-related outcomes: a national population-based cohort study. Arterioscler Thromb Vasc Biol. (2021) 41:175–82. doi: 10.1161/ATVBAHA.120.315551
20. Memel ZN, Lee JF, Foulkes AS, Chung RT, Thaweethai T, Bloom PP. Association of statins and 28-day mortality rates in patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. (2020) 223:19–29. doi: 10.1093/infection/jiaa339
21. Choy D, Chen Q, Goonewardena SN, Pacheco H, Mejia P, Smith RL, et al. Efficacy of statin therapy in patients with hospital admission for covid-19. Cardiovasc Drugs Ther. (2021) 10.1007/s10557-021-02763-2. [Epub ahead of print].
22. Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, Chung CW, Trelles-Garcia VP, Friedman HJ. Atorvastatin associated with decreased hazard for death in covid-19 patients admitted to an icu: a retrospective cohort study. Crit Care. (2020) 24:2269. doi: 10.1186/s13054-020-03154-4
23. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among covid-19 inpatients. Am J Cardiol. (2021) 136:149–55. doi: 10.1016/j.amjcard.2020.09.012
24. Rossi R, Talarico M, Coppi F, Boriani G. Protective role of statins in covid 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. Intern Emerg Med. (2020) 15:1573–6. doi: 10.1007/s11739-020-02504-y
25. Saeed O, Castagna F, Agulliu I, Xue X, Patel SR, Roehlan Y, et al. Statin use and in-hospital mortality in patients with diabetes mellitus and covid-19. J Am Heart Assoc. (2020) 9:e018475. doi: 10.1161/JAHA.120.018475
26. De Spiegeleer A, Bronsecaer A, Teo T, Byttebier G, De Tré G, Belmans L, et al. The effects of arbs, aceis, and statins on clinical outcomes of covid-19 infection among nursing home residents. J Am Med Dir Assoc. (2020) 21:909–14.e2. doi: 10.1016/j.amjmed.2020.06.018
Liu et al. Statin Use in COVID-19

45. Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. *Am J Cardiol.* (2020) 134:153–5. doi: 10.1016/j.amjcard.2020.08.004

46. INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with COVID-19. *Circulation.* (2021)

47. Gaitan-Duarte HG, Alvarez-Moreno C, Rincon-Rodriguez CJ, Yomuya-Taylor E, Liu H, et al. Effect of atorvastatin on the development of antiviral agents and vaccines. *Int J Mol Sci.* (2022) 23: doi: 10.3390/ijms22084177

48. Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, et al. Sensitivity of SARS-CoV-2 B117 to mRNA vaccine-elicited antibodies. *Nature.* (2021) 593:136–41. doi: 10.1038/s41586-021-03412-7

49. Sokal A, Broketa M, Barba-Spaeth G, Meola A, Fernández I, Fourati S, et al. Analysis of mRNA vaccine-elicited B-cell specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 omicron variant. *Immunity.* (2022). doi: 10.1016/j.immuni.2022.04.002. [Epub ahead of print]

50. Wang Z, Muecksch F, Cho A, Gaebler C, Hoffmann H-H, Ramos V, et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins. *Immunity.* (2022). doi: 10.1016/j.immuni.2022.04.003. [Epub ahead of print]

51. Kozlov YM, Wang Z, Yang L. In the age of omicron variant: paclitaxel raises new hopes of covid-19 recovery. *J Med Virol.* (2022) 94:1766–7. doi: 10.1002/jmv.27540

52. Townsend MJ, Kyle TK, Stanford FC. COVID-19 vaccination and obesity: optimism and challenges. *Obesity.* (2021) 29:634–5. doi: 10.1002/obj.23131

53. Sirtori CR. The pharmacology of statins. *Pharmacol Res.* (2014) 88:11–11. doi: 10.1016/j.phrs.2014.03.002

54. Kiortsis DN, Filippatos TD, Mikhailidis DP, El-Saf AF, Liberooulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. *Atherosclerosis.* (2007) 195:7–16. doi: 10.1016/j.atherosclerosis.2006.10.001

55. Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. *Int J Infect Dis.* (2020) 96:615–7. doi: 10.1016/j.ijid.2020.05.115

56. Enojo M. An historical perspective on the discovery of statins. *Proc. Apm Acad. Ser B Biol Sci.* (2010) 368:484–93. doi: 10.1385/pjab:86.484

57. Wang S, Zheng J, Ma L, Petersen RB, Xu L, Huang K. Inhibiting syncytial virus infection by down-regulating rho activity. *J Exp Med.* (2015) 218:229–39. doi: 10.1084/jem.2014130061

58. Mattson M, Castagna M, Allesina A, Mccall K, Hechtman S, et al. Statins inhibit HIV-1 infection by down-regulating viral replication. *Int J Med Virol.* (2002) 70:903–13. doi: 10.1002/ijmv.10040061

59. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. *Antimicrob Agents Chemother.* (2001) 45:1231–7. doi: 10.1128/AAC.45.4.1231-1237.2001

60. South AM, Diz DI, Chappell MC. COVID-19, Acv2, and the cardiovascular consequences. *Am J Physiol Heart Circ Physiol.* (2021) 321:H1084–90. doi: 10.1152/ajpheart.00217.2020

61. Teixeira L, Tempero JR, Pereira-Dutra FS, Ferreira AC, Mattos M, Goncalves BS, et al. Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts. *Front Immunol.* (2022) 13:820133. doi: 10.3389/fimmu.2022.820133

62. Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by west Nile virus perturbs the cellular immune response. *Cell Host Microbe.* (2007) 2:229–39. doi: 10.1016/j.chom.2007.09.003

63. Rothwell C, Labreton A, Young NC, Lim JY, Liu W, Vasudevan S, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. *Virology.* (2009) 389:8–19. doi: 10.1016/j.virol.2009.03.025
100. Koushki K, Shahbaz SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Taba MY, et al. Statin Use in COVID-19 patients: new implications for atherosclerosis. Clin Rev Allergy Immunol. (2021) 60:175–99. doi: 10.1007/s12016-020-08791-9

101. Parsamany N, Moosavi M, Bahrami A, Fereidouni M, Barreto G, Sahebkar A. NLRP3 inflammasome as a treatment target in atherosclerosis: a focus on statin therapy. Int Immunopharmacol. (2019) 73:146–55. doi: 10.1016/j.intimp.2019.05.006

102. Kong Fe, Ye B, Lin L, Cai X, Huang W, Huang Z. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-kB signaling in Pma-stimulated THP-1 monocytes. Biomed Pharmacother. (2016) 82:167–72. doi: 10.1016/j.biopha.2016.04.043

103. Satoh M, Tabuchi T, Itoh T, Nakamura M. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci. (2014) 126:233–41. doi: 10.1042/CS20130043

104. Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. II-18 and II-18: inflammatory markers or mediators of hypertension? Br J Pharmacol. (2014) 171:5589–602. doi: 10.1111/bjp.12876

105. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Bio Chem. (1991) 266:12216–22. doi: 10.1002/jbc.2662141

106. Axelrod ML, Cook RS, Johnson DB, Balko JM. Biological consequences of Mhc-Ii expression by tumor cells in cancer. Clin Cancer Res. (2019) 25:2392–402. doi: 10.1158/1078-0432.CCR-18-3200

107. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, et al. Hmg-Coa reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis. (2004) 172:85–93. doi: 10.1016/j.atherosclerosis.2003.10.002

108. Zhang T, Shao B, Liu GA. Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-γ. Eur Rev Med Pharmacol Sci. (2017) 21:4464–71.

109. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The hmg-coa reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. (2002) 420:78–84. doi: 10.1038/nature01158

110. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PrincE): a randomized trial and cohort study. JAMA. (2001) 286:64–70. doi: 10.1001/jama.286.1.64

111. Smilkovitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with covid-19. Eur Heart J. (2021) 42:2270–9. doi: 10.1093/eurheartj/ehaa1103

112. Arévalo-Lorido JC. Clinical relevance for lowering C-reactive protein with statins. Ann Med. (2016) 48:516–24. doi: 10.1080/07853890.2016.1197413

113. Ruscica M, Ferri N, Macchi C, Corsini A, Sirtori CR. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? Ann Med. (2018) 50:461–84. doi: 10.1080/07853890.2018.1499118

114. Ruscica M, Tokgozoglu L, Corsini A, Sirtori CR. Pcsk9 inhibition and inflammation: a narrative review. Atherosclerosis. (2019) 288:146–55. doi: 10.1016/j.atherosclerosis.2019.07.015

115. Ali MAM, Spinler SA. Covid-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med. (2021) 31:143–60. doi: 10.1016/j.tcm.2020.12.004

116. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. Covid-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. (2020) 136:489–500. doi: 10.1182/blood.2020006529

117. Ferrari E, Martins VM, Teixeira M, Santos RD, Stein R. Covid-19 and thromboinflammation: is there a role for statins? Clinics. (2021) 76:e2518. doi: 10.6061/clinics/2021/e2518

118. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with covid-19. Lancet Haematol. (2020) 7:e438–e40. doi: 10.1016/S2352-3026(20)30145-9

119. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. (2009) 360:1851–61. doi: 10.1056/NEJMoa0900241

120. Doggen CJ, Lemaître RN, Smith NL, Heckbert SR, Putsy BM, HMG. CoA reductase inhibitors and the risk of venous thrombosis
among postmenopausal women. J Thromb Haemost. (2004) 2:700–1. doi: 10.1111/j.1538-7836.2004.00696.x

121. Khamasuwun D, Divietro ML, Tanghahanokk K, Pomerantz SC, Eiger G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med. (2010) 123:60–5. doi: 10.1016/j.amjmed.2009.05.025

122. Rodriguez AL, Wojcik BM, Wroblewski SK, Myers DD, Jr., Wakefield TW, Diaz JA. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Haemostasis. (2012) 33:371–82. doi: 10.1111/j.1747-7456.2012.07986.x

123. Mackman N. Triggers, targets and treatments for thrombosis. Nature. (2008) 451:914–8. doi: 10.1038/nature06797

124. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in covid-19. Am J Hematol. (2020) 95:1578–89. doi: 10.1002/ajh.25982

125. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, et al. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis. (2007) 194:189–95. doi: 10.1016/j.atherosclerosis.2006.07.026

126. Subir R, Jagat JM, Kalyan KG. Pros and cons for use of statins in people with coronavirus disease-19 (Covid-19). Diabetes Metab Syndr. (2020) 14:1225–9. doi: 10.1016/j.dsx.2020.07.011

127. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi D. Kruppel-like factor 2 (Klf2) regulates endothelial thrombotic function. Circ Res. (2005) 97:48–57. doi: 10.1161/01.RES.0000159707.05637.a1

128. Liu A, Wu Q, Guo J, Ares I, Rodriguez JL, Martinez-Larranaga MR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemostas. (2009) 7:514–20. doi: 10.1111/j.1538-7836.2008.03235.x

129. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, et al. Statins differ in their ability to block NF-KappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. (2003) 41:397–401. doi: 10.5411/CPP.1397

130. Lafortore M, Ebulim C, Frere C, Hemadi M, Massaad C, Nuss P, et al. Tissue damage from neutralipid oxidative stress in covid-19. Nat Rev Immunol. (2020) 20:515–6. doi: 10.1038/s41577-020-0407-1

131. Codo AC, Davanzo GG, Monteiro LD, de Souza GF, Muraro SP, Virgilio-da-Silva IV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte type Iia hypercholesterolemia. Am J Hematol. (2020) 95:1578–89. doi: 10.1002/ajh.25982

132. Markle RA, Han J, Summers BD, Yokoyama T, Hajjar KA, Hajjar DP, et al. Oxidative stress-mediated platelet Cd40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. Eur J Clin Pharmacol. (2012) 68:92–103. doi: 10.1177/0091270012449742

133. Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone da-Silva JV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte type Iia hypercholesterolemia. Am J Hematol. (2020) 95:1578–89. doi: 10.1002/ajh.25982

134. Yang S, Shih HJ, Chow YC, Wang TY, Tsai PS, Huang CJ. Simvastatin attenuates testicular injury induced by torsion-detorsion. J Urol. (2010) 184:750–6. doi: 10.1016/j.juro.2010.03.103

135. Pignatelli P, Sanguigni V, Lenti L, Loffredo L, Carnevale R, Sorge R, et al. Oxidative stress-mediated platelet Cd40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost. (2007) 5:1170–8. doi: 10.1111/j.1538-7836.2007.02533.x

136. Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimocia S, et al. Immediate antioxidant and antplatelet effect of atorvastatin via inhibition of Nox2. Circulation. (2012) 126:92–103. doi: 10.1161/CIRCULATIONAHA.112.095554

137. Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. (2014) 24:142–8. doi: 10.1016/j.tcm.2013.09.006

138. Liu A, Wu Q, Guo J, Ares I, Rodriguez JL, Martinez-Larranaga MR, et al. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. (2019) 195:54–84. doi: 10.1016/j.pharmthera.2018.10.004

139. Rodrigues-Diez RR, Tejera-Muñoz A, Rayego-Mateos S, Santos Sanchez L, Marchant V, et al. Statin-Associated muscle symptoms: impact on statin adherence. Am J Hematol. (2020) 95:1099–109. doi: 10.1002/ajh.25982

140. Lin SJ, Chen YH, Lin FY, Hsieh LY, Wang SH, Lin CY, et al. Pravastatin induces thrombomodulin expression in tnfalpha-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. J Cell Biochem. (2007) 101:642–53. doi: 10.1002/jcb.21206
159. Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal consequences of covid-19. *J Bone Joint Surg Am.* (2020) 102:1197–204. doi: 10.2106/JBJS.20.00847

160. Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, et al. Optimizing cholesterol treatment in patients with muscle complaints. *J Am Coll Cardiol.* (2017) 70:1290–301. doi: 10.1016/j.jacc.2017.07.752

161. Li J, Fan YG. Characteristics and mechanism of liver injury in 2019. Coronavirus Disease. *J Clin Transl Hepatol.* (2020) 8:13–7. doi: 10.14218/JCTH.2020.00019

162. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and covid-19. *Nat Rev Endocrinol.* (2021) 17:135–49. doi: 10.1038/s41574-020-00462-1

163. Zhang Y, Xue W, Zhang W, Yuan Y, Zhu X, Wang Q, et al. Histone methyltransferase G9a protects against acute liver injury through Gstp1. *Cell Death Differ.* (2020) 27:1243–58. doi: 10.1038/s41418-019-0412-8

164. Liu C, Wang J, Wei Y, Zhang W, Geng M, Yuan Y, et al. Fat-specific knockout of Meep2 upregulates sPPI to reduce obesity by enhancing browning. *Diabetes.* (2020) 69:35–47. doi: 10.2337/db19-0502

165. Chen H, Huang Y, Zhu X, Liu C, Yuan Y, Su H, et al. Histone demethylase Utx Is a therapeutic target for diabetic kidney disease. *J Physiol.* (2019) 597:1643–60. doi: 10.1113/JP277367

166. Galicia-Garcia U, Jebrai S, Larrea-Sebal A, Uribe KB, Siddiqui H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. *Int J Mol Sci.* (2020) 21:7275. doi: 10.3390/ijms21134725

167. Yang C, Zhang Y, Zeng X, Chen H, Chen Y, Yang D, et al. Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. *J Mol Cell Biol.* (2021) 13:185–96. doi: 10.1038/sj/mcb/mba6003

168. Yang D, Xiao Y, Chen J, Chen Y, Luo P, Liu Q, et al. Covid-19 and chronic renal disease: clinical characteristics and prognosis. *QJM.* (2020) 113:799–805. doi: 10.1037/gjmed/hca258

169. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and outcomes of patients with diabetes and covid-19 in association with glucose-lowering medication. *Diabetes Care.* (2020) 43:1399–407. doi: 10.2337/dc20-0660

170. Mach F, Ray KK, Wilkund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception Vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J.* (2018) 39:2526–39. doi: 10.1093/eurheartj/ehy182

171. Ward NC, Watts GF, Eckel RH. Statin toxicity. *Circ Res.* (2019) 124:328–50. doi: 10.1161/CIRCRESAHA.118.312782

172. Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Assad WF, Murphy SA. Neurological involvement in covid-19 and potential mechanisms: a review. *Neurocrit Care.* (2021) 34:1062–71. doi: 10.1007/s12028-020-01049-4

173. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. (2019). Esc/Eas guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular. *Risk Eur Heart J.* (2020) 41:111–88. doi: 10.1093/eurheartj/ehz455

174. Zhao M, Luo Z, He H, Shen B, Liang J, Zhang J, et al. Decreased low-density lipoprotein cholesterol level indicates poor prognosis of severe and critical covid-19 patients: a retrospective, single-center study. *Front Med.* (2021) 8:585851. doi: 10.3389/fmed.2021.585851

175. Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity of covid-19. *J Clin Lipidol.* (2020) 14:297–304. doi: 10.1016/j.jcllip.2020.04.008

176. Fogacci E, Borghi C, Cicero AFG. Misinterpreting data in lipoidology in the era of covid-19. *J Clin Lipidol.* (2020) 14:543–4. doi: 10.1016/j.jcllip.2020.07.004

177. Black S, Nicolau U, Del Giudice G, Rappuoli R. Influence of statins on influenza vaccine response in elderly individuals. *J Infect Dis.* (2016) 213:1224–8. doi: 10.1093/infdis/jiv456

178. Havers FP, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murphy K, et al. Influenza vaccine effectiveness and statin use among adults in the United States, 2011-2017. *Clin Infect Dis.* (2019) 68:1616–22. doi: 10.1093/cid/ciy780

179. Menni C, Klaser K, May A, Poldori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the covid symptom study app in the UK: a prospective observational study. *Lancet Infect Dis.* (2021) 21:939–49. doi: 10.1016/S1473-3099(21)00224-3

180. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to Covid-19 mRNA vaccine. *Diabetes Metab Res Rev.* (2022) 38:e3465. doi: 10.1002/dmr.3465

181. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for Covid-19: a meta-analysis. *Ann Med.* (2022) 54:516–23. doi: 10.1080/07853890.2022.2034936

182. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral covid antiviral drugs. *Clin Infect Dis.* (2022). doi: 10.1093/cid/ciack180. [Epub ahead of print].

183. Mahase E. Covid-19: pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. *BMJ.* (2021) 375:n2713. doi: 10.1136/bmj.n2713

184. Couzin-Frankel J. Antiviral pills could change pandemic’s course. *Science.* (2021) 374:799–800. doi: 10.1126/science.abc9605

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Yan, Shi, Wang, Peng, Chen and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.